Adjuvant Stereotactic Pelvic Irradiation in Endometrial Cancer (ASPIRE)

King Saud University

Status and phase

Enrolling

Phase 2

Conditions

Endometrial Cancer

Treatments

Radiation: SABR

Study type

Interventional

Funder types

Other

Identifiers

NCT04235179

E-19-4466

Details and patient eligibility

About

Stereotactic Ablative Radiation (SABR/SBRT) will be prescribed to a dose of 30 Gy in 5 fractions, once weekly to the pelvis in post operative patients with endometrial cancer.

Enrollment

30 estimated patients

Sex

Female

Ages

18 to 99 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patient with histologically confirmed endometrial adenocarcinoma
Patient is a candidate for adjuvant pelvic radiation (+/- vault brachytherapy), meeting one of the following conditions: High grade histology OR Outer-half myometrial invasion with any risk factors OR FIGO stage II - IIIC1.
Age ≥18 years.
Patients who are to receive adjuvant systemic therapy in addition to pelvic radiotherapy will be eligible provided that there is at minimum a 3-week interval between any radiation treatment and chemotherapy treatments.

Exclusion criteria

Patient has had prior pelvic radiotherapy.
Patient has Type II endometrial cancer histology (ie. Serous, clear cell or carcinosarcoma).
Patient has a contraindication to pelvic radiotherapy, such as but not limited to a connective tissue disease or inflammatory bowel disease.
Patient has a contraindication to CT contrast.
Patient has a hip prosthesis.